Jonathan Wolleben Analyst PerformanceManaging Director at Citizens JmpJonathan Wolleben is a stock analyst at Citizens Jmp focused in the medical sector, covering 27 publicly traded companies. Over the past year, Jonathan Wolleben has issued 71 stock ratings, including buy and hold recommendations. While full access to Jonathan Wolleben's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jonathan Wolleben's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings120 Last 6 YearsBuy Recommendations95.65% 110 Buy RatingsCompanies Covered27 Unique Companies Ratings Distribution115RatingsDistribution of strong buy, buy, hold, and sell ratings by Jonathan Wolleben.RatingPercentageCount Strong Buy0.0%0 ratings Buy95.7%110 ratings Hold4.3%5 ratings Sell0.0%0 ratingsOut of 115 total stock ratings issued by Jonathan Wolleben at Citizens Jmp, the majority (95.7%) have been Buy recommendations, followed by 4.3% Hold.Best & Worst CallsBest Call0000.0%MBXApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%PRQRSep 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ27 companiesJonathan Wolleben, an analyst at Citizens Jmp, currently covers 27 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical26 companies96.3%Manufacturing1 company3.7%Jonathan Wolleben of Citizens Jmp specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE17 companies63.0%MED - DRUGS8 companies29.6%PHARMACEUTICAL PREPARATIONS2 companies7.4% Jonathan Wolleben's Ratings History at Citizens Jmp Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCRNXCrinetics Pharmaceuticals7/7/2026Downgrade$83.49Hold$0.0000.00% ROIDBVTDBV Technologies6/30/2026Boost Price Target$16.07$55.00Market Outperform$0.0000.00% ROIMIRMMirum Pharmaceuticals6/15/2026Boost Price Target$102.33$146.00Market Outperform$0.0000.00% ROIIRDOpus Genetics6/15/2026Reiterated Rating$4.07$11.00Market Outperform$0.0000.00% ROICRNXCrinetics Pharmaceuticals6/11/2026Reiterated Rating$32.99$95.00Market Outperform$0.0000.00% ROISIONSionna Therapeutics5/26/2026Reiterated Rating$41.13$63.00Market Outperform$0.0000.00% ROISGMTSagimet Biosciences5/19/2026Lower Price Target$6.66$12.00Market Outperform$0.0000.00% ROISPRBSpruce Biosciences5/14/2026Lower Price Target$57.14$150.00Market Outperform$0.0000.00% ROIALTAltimmune5/14/2026Lower Price Target$2.97$11.00Market Outperform$0.0000.00% ROIPHVSPharvaris5/13/2026Lower Price Target$32.08$74.00Market Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. KLRSKalaris Therapeutics5/13/2026Lower Price Target$4.63$25.00Market Outperform$0.0000.00% ROIIRDOpus Genetics5/13/2026Lower Price Target$5.05$11.00Market Outperform$0.0000.00% ROIMBXMBX Biosciences5/12/2026Boost Price Target$40.08$86.00Market Outperform$0.0000.00% ROICRNXCrinetics Pharmaceuticals5/8/2026Lower Price Target$38.03$95.00Market Outperform$0.0000.00% ROIBCRXBioCryst Pharmaceuticals5/7/2026Boost Price Target$8.65$28.00Market Outperform$0.0000.00% ROIPTGXProtagonist Therapeutics5/6/2026Boost Price Target$101.13$137.00Market Outperform$0.0000.00% ROIBMEABiomea Fusion5/5/2026Initiated Coverage$1.48$9.00Market Outperform$0.0000.00% ROIDBVTDBV Technologies5/1/2026Boost Price Target$19.93$55.00Market Outperform$0.0000.00% ROIKALVKalVista Pharmaceuticals4/29/2026Downgrade$26.66Hold$0.0000.00% ROIIRDOpus Genetics4/28/2026Initiated Coverage$5.12$12.00Market Perform$0.0000.00% ROICRNXCrinetics Pharmaceuticals4/28/2026Boost Price Target$38.62$97.00Market Outperform$0.0000.00% ROIMIRMMirum Pharmaceuticals4/21/2026Reiterated Rating$94.25$132.00Market Outperform$0.0000.00% ROIDBVTDBV Technologies3/27/2026Boost Price Target$20.75$47.00Market Outperform$0.0000.00% ROIKALVKalVista Pharmaceuticals3/26/2026Lower Price Target$16.83$28.00Market Outperform$0.0000.00% ROIRYTMRhythm Pharmaceuticals3/17/2026Lower Price Target$90.07$152.00Market Outperform$0.0000.00% ROISPRBSpruce Biosciences3/10/2026Lower Price Target$62.11$170.00Market Outperform$0.0000.00% ROICRNXCrinetics Pharmaceuticals3/2/2026Lower Price Target$41.10$96.00Market Outperform$0.0000.00% ROIRYTMRhythm Pharmaceuticals2/27/2026Boost Price Target$98.07$176.00Market Outperform$0.0000.00% ROIGPCRStructure Therapeutics2/27/2026Lower Price Target$64.75$113.00Market Outperform$0.0000.00% ROIPTGXProtagonist Therapeutics2/26/2026Boost Price Target$86.85$112.00Market Outperform$0.0000.00% ROIMIRMMirum Pharmaceuticals2/26/2026Lower Price Target$92.21$132.00Market Outperform$0.0000.00% ROISIONSionna Therapeutics2/24/2026Initiated Coverage$36.10$63.00Market Outperform$0.0000.00% ROIQNCXQuince Therapeutics1/30/2026Downgrade$0.27Market Perform$0.0000.00% ROIMDGLMadrigal Pharmaceuticals1/20/2026Boost Price Target$501.68$745.00Market Outperform$0.0000.00% ROICRNXCrinetics Pharmaceuticals1/8/2026Lower Price Target$53.34$105.00Market Outperform$0.0000.00% ROIMIRMMirum Pharmaceuticals12/19/2025Boost Price Target$70.28$140.00Market Outperform$0.0000.00% ROIDBVTDBV Technologies12/17/2025Boost Price Target$17.98$45.00Market Outperform$0.0000.00% ROIGPCRStructure Therapeutics12/12/2025Boost Price Target$67.44$120.00Market Outperform$0.0000.00% ROIRYTMRhythm Pharmaceuticals12/12/2025Boost Price Target$117.62$167.00Market Outperform$0.0000.00% ROISGMTSagimet Biosciences11/14/2025Boost Price Target$7.61$35.00Market Outperform$0.0000.00% ROIALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I. (Ad)Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.See Jeff Brown and Marc Chaikin's full analysis and next steps hereSVRASavara11/13/2025Lower Price Target$4.12$10.00Market Outperform$0.0000.00% ROISPRBSpruce Biosciences11/11/2025Set Price Target$115.61$259.00$0.0000.00% ROISPRBSpruce Biosciences11/11/2025Boost Price Target$115.61$259.00Market Outperform$0.0000.00% ROIKALVKalVista Pharmaceuticals11/11/2025Lower Price Target$10.89$28.00Market Outperform$0.0000.00% ROIALTAltimmune11/7/2025Lower Price Target$3.94$14.00Market Outperform$0.0000.00% ROICRNXCrinetics Pharmaceuticals11/7/2025Lower Price Target$43.49$108.00Market Outperform$0.0000.00% ROIPTGXProtagonist Therapeutics11/7/2025Boost Price Target$79.63$102.00Market Outperform$0.0000.00% ROIMIRMMirum Pharmaceuticals11/5/2025Set Price Target$70.97$95.00$0.0000.00% ROIMDGLMadrigal Pharmaceuticals11/5/2025Set Price Target$444.64$527.00$0.0000.00% ROIBCRXBioCryst Pharmaceuticals11/5/2025Lower Price Target$6.76$25.00Market Outperform$0.0000.00% ROIMDGLMadrigal Pharmaceuticals11/5/2025Boost Price Target$444.64$527.00Market Outperform$0.0000.00% ROIMIRMMirum Pharmaceuticals11/5/2025Boost Price Target$70.97$95.00Market Outperform$0.0000.00% ROIKLRSKalaris Therapeutics11/3/2025Initiated Coverage$5.03$20.00Market Outperform$0.0000.00% ROISPRBSpruce Biosciences10/28/2025Set Price Target$123.02$254.00Market Outperform$0.0000.00% ROISVRASavara10/23/2025Boost Price Target$4.11$11.00Market Outperform$0.0000.00% ROIBCRXBioCryst Pharmaceuticals10/15/2025Boost Price Target$6.42$27.00Market Outperform$0.0000.00% ROIATXSAstria Therapeutics10/15/2025Reiterated Rating$11.61Market Perform$0.0000.00% ROIOCULOcular Therapeutix10/1/2025Boost Price Target$11.69$29.00Market Outperform$0.0000.00% ROICRNXCrinetics Pharmaceuticals9/26/2025Boost Price Target$35.89$143.00Market Outperform$0.0000.00% ROIRYTMRhythm Pharmaceuticals9/25/2025Boost Price Target$96.86$142.00Market Outperform$0.0000.00% ROIKALVKalVista Pharmaceuticals9/12/2025Boost Price Target$14.81$28.00Market Outperform$0.0000.00% ROIMDGLMadrigal Pharmaceuticals8/20/2025Boost Price Target$379.55$485.00Market Outperform$0.0000.00% ROILRMRLarimar Therapeutics8/15/2025Lower Price Target$4.30$18.00Market Outperform$0.0000.00% ROIPHVSPharvaris8/13/2025Lower Price Target$21.47$52.00Market Outperform$0.0000.00% ROIATXSAstria Therapeutics8/13/2025Boost Price Target$6.88$26.00Market Outperform$0.0000.00% ROIQNCXQuince Therapeutics8/12/2025Lower Price Target$314.00$1,600.00Market Outperform$0.0000.00% ROICRNXCrinetics Pharmaceuticals8/11/2025Lower Price Target$26.85$86.00Market Outperform$0.0000.00% ROIGPCRStructure Therapeutics8/7/2025Lower Price Target$16.31$87.00Market Outperform$0.0000.00% ROIPTGXProtagonist Therapeutics8/7/2025Boost Price Target$53.42$69.00Market Outperform$0.0000.00% ROIMIRMMirum Pharmaceuticals8/7/2025Set Price Target$59.41$81.00Market Outperform$0.0000.00% ROIRYTMRhythm Pharmaceuticals8/6/2025Boost Price Target$89.85$135.00Market Outperform$0.0000.00% ROIALTAltimmune7/10/2025Lower Price Target$4.21$15.00Market Outperform$0.0000.00% ROIKALVKalVista Pharmaceuticals7/8/2025Boost Price Target$15.69$27.00Market Outperform$00.0000.00% ROIPRQRProQR Therapeutics6/27/2025Reiterated Rating$2.16$8.00Market Outperform$0.0000.00% ROIRYTMRhythm Pharmaceuticals6/26/2025Reiterated Rating$62.19$84.00Market Outperform$000.0000.00% ROIDBVTDBV Technologies6/26/2025Reiterated Rating$9.06$21.00Market Outperform$00.0000.00% ROISKYESkye Bioscience6/24/2025Reiterated Rating$3.16$15.00Market Outperform$0.0000.00% ROIGPCRStructure Therapeutics6/23/2025Reiterated Rating$21.73$89.00Market Outperform$00.0000.00% ROIDBVTDBV Technologies5/27/2025Boost Price Target$8.41$21.00Market Outperform$00.0000.00% ROIAURAAura Biosciences5/23/2025Reiterated Rating$5.91$19.00Market Outperform$0.0000.00% ROICLSDClearside Biomedical5/16/2025Reiterated Rating$13.23$75.00Market Outperform$0.0000.00% ROIMIRMMirum Pharmaceuticals5/9/2025Boost Price Target$45.07$76.00Market Outperform$000.0000.00% ROIMDGLMadrigal Pharmaceuticals4/24/2025Reiterated Rating$308.00$443.00Market Outperform$000.0000.00% ROIMBXMBX Biosciences4/10/2025Initiated Coverage$6.12$38.00Market Outperform$00.0000.00% ROIAURAAura Biosciences3/26/2025Set Price Target$5.25$19.00$0.0000.00% ROIPTGXProtagonist Therapeutics2/7/2025Reiterated Rating$39.61$58.00Market Outperform$00.0000.00% ROIATXSAstria Therapeutics1/31/2025Initiated Coverage$7.49$26.00Outperform$00.0000.00% ROIKALVKalVista Pharmaceuticals1/31/2025Initiated Coverage$8.77$19.00Outperform$00.0000.00% ROIPHVSPharvaris1/31/2025Boost Price Target$18.06$55.00Market Outperform$00.0000.00% ROIBCRXBioCryst Pharmaceuticals1/31/2025Reiterated Rating$7.96$18.00Market Outperform$0.0000.00% ROITrump’s $250 Bill – See Immediately (Ad)Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in modern history - larger than Paul Tudor Jones' Black Monday bet and Michael Burry's $700 million Big Short. While most investors chase AI stocks, insiders including Ray Dalio and Tudor Jones have quietly repositioned. The last comparable shock sent certain stocks up 2,464%, 2,778%, and even 13,000% - turning a $10,000 stake into over $1.3 million. Dr. Eifrig has identified one stock at the center of this story and released a free broadcast to help investors act before the window closes.Watch the free broadcast now and learn where to position your moneyDBVTDBV Technologies1/10/2025Reiterated Rating$4.14$10.00Market Outperform$00.0000.00% ROIMDGLMadrigal Pharmaceuticals1/10/2025Reiterated Rating$330.62$427.00Market Outperform$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyRoyal Bank Of CanadaWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftRaymond James Financial Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.